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smoking controls), 88% sensitivity and 92% specificity (COPD 
vs. nonsmoking controls) and 92.3% sensitivity and 83.3% 
specificity (GOLD I/II vs. GOLD III/IV). Acetone and indole 
were identified as two of the discriminating exhaled mole-
cules.  Conclusions: We conclude that real-time MS may be a 
useful technique to analyze and characterize the metabo-
lome of exhaled breath. The acquisition of breathprints in a 
rapid manner may be valuable to support COPD diagnosis 
and to gain insight into the disease.  © 2014 S. Karger AG, Basel 
 Introduction 
 Chronic obstructive pulmonary disease (COPD) is a 
complex illness, which is sometimes difficult to properly 
diagnose and for which many fundamental questions re-
main unanswered  [1] . There is a clear need to increase our 
knowledge of the COPD phenotype for the ultimate pur-
pose of improving diagnostics  [2] .
 Taking samples from the lung itself (e.g. induced spu-
tum) to perform analytical measurements can be difficult, 
and for this reason the analysis of exhaled breath is elicit-
ing considerable interest as it offers the unique advantage 
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 Abstract 
 Background: It has been suggested that exhaled breath 
contains relevant information on health status.  Objectives: 
We hypothesized that a novel mass spectrometry (MS) tech-
nique to analyze breath in real time could be useful to dif-
ferentiate breathprints from chronic obstructive pulmonary 
disease (COPD) patients and controls (smokers and non-
smokers).  Methods: We studied 61 participants including 25 
COPD patients [Global Initiative for Obstructive Lung Dis-
ease (GOLD) stages I–IV], 25 nonsmoking controls and 11 
smoking controls. We analyzed their breath by MS in real 
time. Raw mass spectra were then processed and statistical-
ly analyzed.  Results: A panel of discriminating mass-spectral 
features was identified for COPD (all stages; n = 25) versus 
healthy nonsmokers (n = 25), COPD (all stages; n = 25) versus 
healthy smokers (n = 11) and mild COPD (GOLD stages I/II; 
n = 13) versus severe COPD (GOLD stages III/IV; n = 12). A 
blind classification (i.e. leave-one-out cross validation) re-
sulted in 96% sensitivity and 72.7% specificity (COPD vs. 
 Received: June 10, 2013 
 Accepted after revision: December 3, 2013 
 Published online: February 19, 2014 
 Renato Zenobi 
 ETH Zurich 
 Department of Chemistry and Applied Biosciences 
 CH–8093 Zurich (Switzerland) 
 E-Mail zenobi   @   org.chem.ethz.ch 
 © 2014 S. Karger AG, Basel
0025–7931/14/0874–0301$39.50/0 
 www.karger.com/res 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
3/
20
16
 2
:4
2:
30
 P
M
 Martinez-Lozano Sinues   et al.
 
Respiration 2014;87:301–310
DOI: 10.1159/000357785
302
of probing the lung itself, but in a noninvasive fashion  [3, 
4] . As a result, in recent years, a number of techniques 
have been developed to analyze exhaled breath for inves-
tigating COPD among other lung diseases. These include 
the analysis of exhaled-breath condensate  [5–12] , exhaled 
particles  [13] and volatile compounds  [14–20] . Even 
trained dogs seem to be able to recognize the peculiar 
scent of COPD in exhaled breath  [21] .
 A new mass spectrometry (MS) technique has been de-
veloped which aims to detect trace compounds in breath 
or any other matrix in real time  [22–28] . This technique 
has been termed secondary electrospray ionization MS 
(SESI-MS, also dubbed ‘extractive electrospray ioniza-
tion’)  [29] , and in a clinical context, it has shown promise 
for the diagnosis of bacterial infections based on their 
emitted volatile ‘breathprints’  [30–34] . This study seeks to 
expand SESI-MS applications in order to develop nonin-
vasive techniques to characterize COPD through exhaled 
breath. In particular, the aim of this exploratory study was 
to assess, for the first time, whether or not SESI-MS holds 
promise to be able to identify subjects with COPD. Given 
that this technique has never been used to study any lung 
disease, the type of response of SESI-MS to be expected in 
such cases was completely unknown. For this reason, we 
deliberately chose to include a young and healthy control 
group. The aim was to establish the lower and upper 
bounds to be expected in future measurements with age-
matched controls, similar to previous pilot studies on 
breath analysis  [35] . We nevertheless attempted to charac-
terize potential differences between COPD patients with 
the mild or moderate stages [Global Initiative for Obstruc-
tive Lung Disease (GOLD) I/II] and the severe or very se-
vere stages (GOLD III/IV) of the disease. We therefore 
analyzed the breath of this heterogeneous group and ap-
plied statistical methods to reveal whether or not differ-
ences in breath patterns would be observable in such cases.
 Material and Methods 
 Subjects 
 A group of 61 subjects participated in this study: 25 healthy 
nonsmokers, 11 healthy asymptomatic smokers and 25 patients 
affected by COPD.
 Inclusion criteria for subjects with COPD were: males and fe-
males aged between 40 and 75 years, objectively diagnosed with 
COPD according to the GOLD guidelines  [36] . Exclusion criteria 
were: having (1) a mental or physical disability precluding in-
formed consent or compliance with the protocol, and (2) an acute 
exacerbation of COPD within the last 6 weeks.
 Inclusion criteria for nonsmoking controls were: males and fe-
males aged between 18 and 75 years with no clinical signs of lung 
disease. Exclusion criteria were: (1) having a mental or physical 
disability precluding informed consent or compliance of the pro-
tocol; (2) being pregnant, and (3) being a current smoker.
 Inclusion criteria for smoking controls were: (1) males and fe-
males aged between 18 and 75 years with no clinical signs of lung 
disease, and (2) being a current smoker. Exclusion criteria were: 
(1) having a mental or physical disability precluding informed 
consent or compliance with the protocol, and (2) being pregnant.
 The COPD stage (i.e. severity of airflow limitation) was as-
sessed based on post-bronchodilator forced expiratory volume in 
1 s (FEV 1 ). As a result, 13 COPD patients were diagnosed as mild 
or moderate (GOLD stages I/II) and 12 were diagnosed as severe 
or very severe (GOLD stages III/IV). Two out of the 25 COPD pa-
tients had never smoked, while 18 were ex-smokers and 5 were still 
smoking.
 The participants were asked not to smoke, eat, drink (except 
water) or brush their teeth (including the use of mouthwash or 
sprays) for at least 1 h before the measurements were performed. 
Subjects were randomly allocated to measurement slots in order to 
prevent any bias due to instrument drift.
 The study was carried out in accordance with the Declaration 
of Helsinki of the World Medical Association. The local ethics 
committee approved the study (COPD patients EK-NR: 2011-
0106 and healthy controls: EK 2012-N-49) and all subjects gave 
their written informed consent to participate. Measurements took 
place between March 3 and June 5, 2012.
 Mass Spectrometry Measurements 
 The experimental set-up was previously presented in detail  [22, 
24, 26, 28, 30–34, 37] . Briefly, the entrance of a commercial quad-
rupole time-of-flight mass spectrometer (Ultima, Waters, Milford, 
Mass., USA) was slightly modified to allow for the admission of 
breath samples through a heated Teflon tube. Exhaled breath was 
mixed with a nanoelectrospray plume (water and 0.2% formic 
acid), whereby some compounds present in the breath were read-
Table 1. Characteristics of study subjects
GOLD
III/IV
(n = 12)
GOLD
I/II
(n = 13)
Healthy
smokers
(n = 11)
Healthy 
nonsmokers
(n = 25)
Age, years 62 ± 5 63 ± 7 34 ± 10 27 ± 9
Male/female 3/9 9/4 9/2 18/7
Smoking status
Non/ex/current 1/10/1 1/8/4 0/0/11 24/1/0
Pack-years 37 ± 23 40 ± 32 10 ± 13 0
BMI 23 ± 4 31 ± 7 28 ± 4 23 ± 3
FEV1 % predicted 27 ± 6 70 ± 13 111 ± 10 101 ± 9
FEV1 0.6 ± 0.1 2.1 ± 0.6 4.5 ± 0.6 4.1 ± 0.8
FVC % predicted 74 ± 15 92 ± 15 111 ± 12 105 ± 10
FVC 2.1 ± 0.5 3.4 ± 1 5.4 ± 0.9 5 ± 1.1
FEV1/FVC 31 ± 7 63 ± 6 83 ± 4 82 ± 7
GOLD stage
I/II/III/IV 2/10 2/11 0 0
 Values are mean ± SD.
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ily detected in real time. The mass spectrometer was operated in 
the positive-ion mode. The subjects were asked to provide a deep 
exhalation through a disposable mouth piece, while keeping the 
pressure through the sampling tube at 20 mbar (monitored by a 
digital manometer), thereby ensuring that each subject breathed at 
the same flow rate (approx. 1.8 liters/min). This process was re-
peated 6 times per subject, with the 6 replicate measurements tak-
ing typically  ≤ 10 min. Online supplementary figure S1 (www.
karger.com/doi/10.1159/000357785) shows a picture of a SESI-MS 
breath analysis set-up.
 Statistical Analysis 
 The mass spectra, comprising the last few seconds of each ex-
halation, which reflects the exhaled composition of the lower re-
spiratory tract, were averaged via Masslynx (i.e. Water’s software) 
and exported as text files. These raw mass spectra were then pro-
cessed using the commercial software MATLAB (R2012a, Math-
works Inc., Natick, Mass., USA). The original mass spectra were 
interpolated to 10,000 mass-to-charge (m/z) values (56–400 Da; 
binned to Δm/z = 0.0187 Da). The spectra were normalized by 
standardizing the area under the curve to the median. The local 
maxima of each peak were identified, resulting in 1,260 features 
with a threshold intensity of 10 counts. The 6 replicate measure-
ments of each subject were averaged and, finally, a 61 × 1,260 ma-
trix was assembled. The 61 participants were allocated to 1 of the 
following groups: healthy nonsmokers, healthy smokers, mild 
COPD (GOLD I/II) and severe COPD (GOLD III/IV).
 The analysis was conducted by pairs of groups separately: 
COPD (all stages; n = 25) versus healthy nonsmokers (n = 25), 
COPD (all stages; n = 25) versus healthy smokers (n = 11) and mild 
COPD (GOLD I/II; n = 13) versus severe COPD (GOLD III/IV; 
n = 12).
 We first sought to reduce the dimensionality of the matrices by 
extracting the most significant features to discern these 4 groups. 
In this way, the noisiest peaks stemming from background air, 
chemical noise, etc. were largely excluded from the subsequent 
analysis. To do so, a Mann-Whitney U test was performed, looping 
each of the 1,260 m/z values  [38] . To prevent the inclusion of the 
noisiest peaks in further analysis, we did not consider the signal if 
the median for the 2 groups compared was <50 counts. Upon per-
formance of the Mann-Whitney U test, only the signals with p val-
ues <0.05 (chosen significance level) were retained (4 for mild vs. 
severe, 37 for COPD vs. nonsmoking controls and 69 for COPD 
vs. smoking controls).
 Thus, the original data was reduced to matrices of 25 × 4 
(GOLD I/II vs. GOLD III/IV), 36 × 69 (COPD vs. smoking con-
trols) and 50 × 37 (COPD vs. nonsmoking controls). To enable 
visualization of these data, the matrices were autoscaled  [39] and 
subjected to principal component analysis  [40] . Finally, the predic-
tion power of these subsets of signals was assessed. A  k -nearest 
neighbor ( k -NN; Euclidean distance) classification algorithm was 
used to predict the class of a given breath spectrum in a leave-one-
out cross validation exercise (i.e. each of the samples was left out 
of the model once and classified).
 Results 
 Subjects 
 The baseline characteristics of the 4 subgroups are 
shown in  tables 1 and  2 . As expected, FEV 1 and FVC val-
ues in COPD patients were lower than in both smoking 
and nonsmoking controls. Patients with COPD were old-
er, had smoked more pack-years than the controls and 
were being treated with various medications, including 
inhalational COPD therapy. However, the 2 COPD sub-
groups showed comparable characteristics.
 Mass-Spectral Breathprints 
 Figure 1 shows the typical ion intensity as a function 
of time for 4 selected m/z values present in the breath of 
a random selection of 12 subjects. Each trace (m/z 59, 205, 
253 and 343) corresponds to one compound present in 
breath for at least 1 of the 12 participants (labeled 1–12 at 
the top of the m/z 59 trace). Subjects 2, 3 and 4 are COPD 
patients. Each subject breathed 6 consecutive times, the 
whole process taking typically <10 min/subject. For ex-
ample, for the trace at m/z 59, it is clearly observable how 
the ion intensity rises above the background level 6 times 
Table 2.  Study subjects’ medication
Medication GOLD III/IV
(n = 12)
GOLD I/II
(n = 13)
Healthy smokers
(n = 11)
Healthy non-
smokers (n = 25)
Short-acting beta-2-sympathicomimetic 8 1 0 0
Long-acting beta-2-sympathicomimetic 11 5 0 0
Short-acting anticholinergic 1 0 0 0
Long-acting anticholinergic 10 4 0 0
Inhalational steroid 11 4 0 0
Antihypertensive medication 5 9 0 0
Antidiabetic medication 1 1 0 0
Statin 4 4 0 0
Long-term oxygen 1 0 0 0
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for all 12 subjects. This particular compound corresponds 
to acetone, as it has been previously characterized  [22] . 
For each individual, the height (intensity) of the acetone 
peaks is very similar for the 6 breaths, indicating a satis-
factory repeatability (average of 12% RSD for the 61 par-
ticipants) and robustness of the measurements, even for 
COPD patients ( fig.1 – see zoom of acetone-subject 3), 
but clearly different among individuals  [41] .
 Discrimination of Study Groups 
 The collected breath mass spectra were processed sta-
tistically with the aim of ultimately discriminate the study 
groups.  Figure 2 (left) shows 3 box plots corresponding 
to 3 representative features found in this study to yield a 
p value of <0.05 after a Mann-Whitney U test. The right 
plot shows a zoom of the mass spectrum in the region of 
interest with all the traces corresponding to each partici-
pant overlaid. The top peak, which corresponds to ace-
tone, was found significantly increased in COPD versus 
healthy smokers (p < 0.01). The middle graph (m/z 118) 
was found to be significantly (p < 0.005) decreased in 
COPD patients’ breath compared to the healthy non-
smoking controls. The bottom graph shows an example 
of one peak found to be increased in GOLD stages III/IV 
vs. I/II (p < 0.05).  Tables 3–5 list the remaining peaks 
found in this study to be differently exhaled among the 
different groups under study.  Figure 3 shows the corre-
sponding principal component analysis plots for the sig-
nals listed in  tables 3–5 .
 Finally, we tested whether these sets of exhaled com-
pounds may be used to predict the presence/absence of 
disease and disease stage.  Table 6 summarizes the classi-
fication results for the 3 binary comparisons performed, 
where 24/25 COPD patients and 8/11 smokers, 22/25 
COPD patients and 23/25 nonsmokers and 12/13 GOLD 
stages I/II and 10/12 GOLD stages III/IV were correctly 
classified for each of the 3 leave-one-out cross-valida-
tions.
m/z 59
m/z 59
m/z 205
m/z 253
m/z 343
42 545250484644 56
1 2
3 4
5 6 7 8 9
10
11 12
Re
la
tiv
e 
in
te
ns
ity
0 16014012010080604020 180
Time (min)
 Fig. 1. Time trace of the ion current for 4 selected m/z values (59, 
201, 253 and 351) monitored in the breath of 12 randomly selected 
subjects. Individuals labeled as 2, 3 and 4 correspond to COPD 
patients (GOLD stages IV, IV and II, respectively), while the rest 
of the subjects shown in this example were nonsmoking controls. 
Each subject provided 6 consecutive breath samples. The top trace 
shows a zoom at m/z 59 (acetone) of the 6 replicate measurements 
of one of the COPD patients. It illustrates that excellent repeatabil-
ity can be obtained even in cases of impaired breathing capacity. 
Note also how each subject shows a distinct breathprint. 
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 Fig. 2. Examples of compounds found to be exhaled at different 
concentrations between COPD subjects and smoking controls 
(top), COPD subjects and nonsmoking controls (middle) and 
those with COPD GOLD stages I/II and III/IV (bottom). The fea-
ture at m/z 59 corresponds to acetone and the one at m/z 118 to 
indole (most probable identity).  *  p < 0.05,  * *  p < 0.01 and  * * *  p < 
0.005. 
Table 3.  Mass-spectral features found to be exhaled at significant-
ly (p < 0.05) different concentrations by COPD subjects and non-
smoking controls
m/z COPD subjects Nonsmoking controls
79 63 (49 – 77) 102 (65 – 138)
102.1 134 (111 – 156) 191 (160 – 221)
118.0 120 (60 – 180) 217 (134 – 300)
143.1 931 (684 – 1,179) 1,218 (1,025 – 1,411)
157.1 664 (531 – 798) 844 (744 – 945)
158.1 557 (459 – 656) 723 (632 – 814)
160.1 214 (164 – 263) 335 (262 – 409)
174.1 338 (264 – 413) 391 (344 – 438)
180.1 541 (180 – 901) 623 (300 – 946)
185.1 493 (426 – 560) 580 (526 – 635)
185.9 62 (53 – 72) 77 (70 – 84)
186.2 496 (381 – 610) 956 (654 – 1,258)
188.1 284 (232 – 337) 357 (309 – 406)
190.1 301 (242 – 360) 393 (335 – 451)
202.2 268 (229 – 308) 416 (302 – 529)
227.1 722 (548 – 896) 509 (379 – 639)
240.2 152 (130 – 174) 216 (173 – 259)
245.2 228 (200 – 256) 193 (152 – 233)
247.2 386 (313 – 458) 320 (222 – 418)
258.1 161 (138 – 184) 203 (174 – 232)
265.1 129 (86 – 171) 114 (111 – 118)
268.2 95 (80 – 110) 119 (102 – 136)
271 110 (88 – 131) 78 (71 – 86)
271.3 912 (682 – 1,141) 614 (433 – 796)
277.1 160 (108 – 212) 107 (88 – 125)
287.3 218 (147 – 288) 125 (102 – 148)
327 419 (364 – 473) 484 (439 – 528)
328 54 (50 – 59) 62 (57 – 66)
329 416 (361 – 471) 477 (433 – 520)
329.3 111 (80 – 141) 77 (48 – 106)
330 60 (55 – 64) 67 (63 – 71)
331 148 (131 – 164) 165 (152 – 179)
332.2 71 (63 – 79) 95 (84 – 106)
344.1 270 (218 – 321) 362 (316 – 408)
345 58 (54 – 63) 67 (61 – 73)
346 256 (205 – 307) 359 (312 – 406)
348.1 103 (84 – 121) 134 (118 – 149)
 The signal intensity values listed are means (95% confidence 
interval) in units of counts.
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m/z COPD subjects Smoking controls
59 2,155 (1,644 – 2,666) 1,042 (752 – 1,332)
60.1 168 (136 – 200) 95 (78 – 111)
98 38 (27 – 50) 74 (36 – 112)
122 85 (70 – 99) 133 (105 – 160)
123.1 220 (98 – 342) 746 (219 – 1,274)
124.1 86 (59 – 113) 191 (110 – 272)
126 71 (40 – 102) 223 (81 – 365)
146 132 (78 – 187) 335 (128 – 543)
150 111 (81 – 141) 241 (112 – 370)
155.1 1,280 (617 – 1,943) 468 (260 – 677)
160.1 235 (164 – 306) 433 (252 – 614)
172.1 553 (411 – 695) 288 (102 – 475)
182 68 (41 – 95) 186 (62 – 309)
189.1 195 (154 – 237) 132 (102 – 162)
191.1 366 (323 – 408) 271 (210 – 333)
194.1 105 (75 – 136) 181 (103 – 259)
195.2 1,856 (1,448 – 2,265) 1,065 (475 – 1,655)
198.1 167 (144 – 191) 115 (91 – 139)
199.1 435 (374 – 497) 282 (173 – 391)
201.1 345 (284 – 407) 228 (179 – 278)
203.1 417 (326 – 509) 235 (118 – 352)
204.1 361 (302 – 421) 241 (132 – 351)
205.2 553 (158 – 948) 237 (137 – 338)
207.1 1,159 (924 – 1,394) 981 (19 – 1,943)
208.2 508 (394 – 621) 390 (35 – 745)
211.2 342 (288 – 395) 229 (166 – 293)
213.1 299 (244 – 354) 214 (166 – 263)
214 156 (132 – 181) 106 (70 – 142)
214.1 232 (195 – 270) 165 (123 – 208)
215.1 272 (236 – 308) 166 (111 – 221)
218.1 294 (243 – 345) 216 (135 – 298)
222.2 224 (181 – 266) 275 (–49 to 599)
223.1 1,390 (1,109 – 1,670) 954 (833 – 1,075)
224.1 317 (250 – 384) 242 (210 – 273)
227.1 722 (548 – 896) 538 (–29 to 1,105)
228.2 215 (181 – 250) 186 (36 – 335)
Table 4.  Mass-spectral features found to be exhaled at significantly (p < 0.05) different concentrations by COPD subjects and smoking 
controls
m/z COPD subjects Smoking controls
235.2 1,173 (949 – 1,397) 747 (173 – 1,321)
236.2 287 (218 – 355) 209 (70 – 348)
239.2 168 (142 – 194) 131 (109 – 153)
241.2 141 (123 – 158) 112 (79 – 145)
244.2 578 (461 – 695) 621 (–96 to 1,338)
247.2 386 (313 – 458) 287 (128 – 446)
249.2 279 (196 – 362) 189 (161 – 216)
251.2 186 (167 – 206) 150 (129 – 172)
253.1 138 (99 – 178) 106 (90 – 122)
255.1 258 (–17 to 532) 98 (89 – 107)
256.2 164 (78 – 250) 96 (69 – 122)
257.2 253 (–11 to 518) 84 (42 – 126)
258.1 161 (138 – 184) 121 (85 – 157)
267.2 172 (152 – 192) 129 (95 – 163)
269.2 104 (92 – 117) 76 (61 – 92)
271.3 912 (682 – 1,141) 357 (30 – 684)
272.3 265 (212 – 318) 146 (64 – 227)
273.2 96 (81 – 111) 66 (48 – 84)
276.2 131 (102 – 160) 246 (–121 to 612)
279.2 1,536 (1,310 – 1,762) 1,111 (839 – 1,384)
285.2 338 (53 – 623) 100 (57 – 143)
288.3 474 (363 – 586) 309 (69 – 550)
288.9 34 (28 – 39) 68 (43 – 93)
289.3 150 (121 – 179) 101 (43 – 159)
298.9 50 (40 – 60) 74 (51 – 97)
299.3 258 (136 – 381) 74 (48 – 101)
316.3 194 (100 – 289) 68 (32 – 103)
317.3 82 (59 – 105) 49 (37 – 62)
319.1 43 (34 – 53) 55 (42 – 68)
323.1 37 (30 – 44) 48 (36 – 59)
325.1 36 (28 – 45) 60 (38 – 82)
329.3 111 (80 – 141) 45 (10 – 80)
330.3 65 (52 – 79) 34 (18 – 50)
 The signal intensity values are listed as means (95% confidence 
interval) in units of counts.
Table 5.  Mass spectral features found to be exhaled at significantly 
(p < 0.05) different concentrations by both COPD subgroups
m/z GOLD I/II GOLD III/IV
165 277 (210 – 344) 210 (178 – 242)
286.3 70 (56 – 84) 228 (6 – 451)
302.3 63 (46 – 80) 358 (21 – 695)
308.2 53 (17 – 90) 55 (41 – 70)
 The signal intensity values listed are means (95% confidence 
interval) in units of counts.
Table 6.  Summary of the leave-one-out cross-validation for the 3 
classifications
COPD (n = 25) 
vs. smokers
(n = 11)
COPD (n = 25)
vs. nonsmokers
(n = 25)
GOLD I/II 
(n = 13) vs.
GOLD III/IV 
(n = 12)
Sensitivity 96.0% 88.0% 92.3%
Specificity 72.7% 92.0% 83.3%
Positive predictive 
value 88.9% 91.7% 85.7%
Negative predictive 
value 88.9% 88.5% 90.9%
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 Discussion 
 The analysis of exhaled breath is believed to hold 
promise in the study of lung diseases since exhaled air is 
in direct contact with the respiratory tract and therefore 
may carry relevant biological markers. For this reason, 
quite some efforts have been devoted over the last years 
to develop instrumentation and methods capable of de-
tecting exhaled biomarkers for a number of lung diseases, 
including COPD  [42] .
 For example, the analysis of exhaled-breath conden-
sate, covering molecules ranging from small metabolites 
to large proteins  [3] , has been shown to shed light on the 
disease phenotype  [5, 7] . The main drawback of analyzing 
exhaled-breath condensate is likely associated with the 
difficulty to standardize sample collection. For this rea-
son, new sample collection techniques are currently un-
der development and investigation  [13, 43] .
 Another technology targeting exhaled breath is the so-
called electronic nose, which responds to combinations 
of volatiles present in breath providing breathprints ame-
nable for statistical analysis  [15, 16] . However, this tech-
nology is not suitable to provide structural elucidation of 
the breath compounds providing separation among dif-
ferent cohorts, which is crucial for gaining insight into 
underlying biochemical COPD mechanisms. On the oth-
er hand, an advantageous feature is the portability of 
these devices. Similarly, gas chromatography ion mobil-
ity spectrometry provides good portability and pattern 
identification, but lacks unambiguous structural identifi-
cation capabilities  [14, 17] .
 Complementarily to these techniques, breath can be 
analyzed by MS, either off-line (e.g. gas chromatography 
MS  [15, 44] ) or in real time by a number of different tech-
niques. The main advantage of MS is its selectivity (espe-
cially high-resolution instruments), which enables a wide 
analyte coverage as well as the structural identification of 
the components detectable in breath. There are mainly 
three different approaches to analyze breath in real time: 
proton transfer reaction MS  [45] , selected ion flow tube 
MS  [46] and SESI-MS.
 In real-time techniques (i.e. no sample collection-
manipulation), the risks of introducing artifacts due to 
sample handling are minimized. Not only is the acquisi-
tion of the breathprint data fast, but also the complete 
processing and classification of the spectra afterwards 
can be performed rapidly. For example, the whole pro-
cess including the 6 replicate breath analyses and the 
statistical classification (diagnosis) can be accomplished 
in 10 min. Currently, the main drawback of SESI-MS, as 
15
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 Fig. 3. 3-Dimensional principal component analysis (PCA) plot of 
the mass-spectral breathprints containing the most significant fea-
tures of COPD subjects and smoking controls ( a ), COPD subjects 
and nonsmoking controls ( b ) and subjects with COPD GOLD 
stages I/II and III/IV ( c ). As expected, clustering according to 
health status is more obvious in the COPD vs. healthy controls ( a , 
 b ) than in the COPD subgroups ( c ). 
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opposed to electronic noses, for example, is the lack of 
portability.
 All the real-time MS techniques available nowadays 
can detect compounds of relatively high volatility, e.g. ac-
etone, which is a well-known metabolite present in breath 
 [47, 48] ( fig. 1 ,  2 , m/z 59). However, the excellent sensitiv-
ity of SESI-MS (down to parts-per-trillion  [24, 49] ) offers 
the opportunity to target a set of molecules never ob-
served before in breath in real time  [22–24, 50] . A recent 
model has proposed that ionization at atmospheric pres-
sure leads to higher ionization efficiencies, which may ex-
plain SESI-MS efficiency in this relatively high m/z range 
 [51] . Notice, for example, that species with molecular 
weights as large as m/z 343 are clearly detectable ( fig. 1 ). 
Another example is the data in  tables 3–5 , where masses 
well beyond m/z 200 (the typical m/z limit of other on-
line techniques) strongly contribute to discerning COPD 
patients and controls. Indeed, it is reasonable to hypoth-
esize that more complex (heavier) biomolecules may car-
ry more accurate information since they may be linked to 
just one particular biochemical process, rather than to 
several.
 In contrast with electronic noses, for example, one ma-
jor advantage of MS is that it allows for the chemical char-
acterization of the detected exhaled molecules. For ex-
ample, by further fragmentation measurements, the ion 
seen at m/z 59 was assigned to acetone  [22] , which is an 
intermediate of the synthesis and degradation of ketone 
bodies and propanoate metabolism (http://www.kegg.jp/
dbget-bin/www_bget?cpd:C00207). In this study, ace-
tone was found to be exhaled in lower concentrations in 
the smokers group than among the COPD patients 
( fig. 2 ).
 In the second phase of our study, we had access to a 
high-resolution instrument with fragmentation capabili-
ties (Waters’ Synapt G2S). While the identification with 
high confidence of the large number of compounds found 
in breath via SESI-MS is ongoing, we anticipate here that, 
based on accurate mass, isotopic pattern and MS/MS 
data, the peak at m/z 118 corresponds to indole. It was 
also tentatively identified in breath via selected ion flow 
tube MS  [52] and it has been unambiguously detected off-
line (gas chromatography MS). Recently, it was found to 
be increased in humans who are under stress  [53] , and in 
patients suffering liver malfunction compared to a healthy 
cohort, it was found to be decreased  [54] . Indole is one 
metabolite involved in tryptophan metabolism (http://
www.kegg.jp/dbget-bin/www_bget?cpd:C00463) and 
binds to albumin in blood  [55] . At present, the reasons 
why indole may be decreased in COPD patients’ breath 
are unclear and this finding is under further investigation 
for confirmation.
 Another interesting observation made is that the com-
bination of the large number of different components de-
tectable in breath by SESI-MS provides a sort of unique 
‘fingerprint’ for each individual, observable even by vi-
sual inspection ( fig. 1 ). The existence of individual meta-
bolic phenotypes, which seem to be stable during pro-
longed periods, has been hypothesized and experimental 
evidence has been published  [56] . Previous  [24] and re-
cent  [41] investigations by our group support this hy-
pothesis via the analysis of exhaled breath. This finding 
has important implications in personalized healthcare 
 [57] since, for example, it is conceivable to monitor health 
status through breath in an individualized fashion (e.g. 
monitoring of COPD exacerbation episodes and response 
to medication).
 Our study has some limitations. At this exploratory 
stage, we selected a heterogeneous control group involv-
ing young healthy smokers and nonsmokers, with the aim 
that differences among the groups be readily observable. 
This was indeed the case, and therefore current efforts are 
being devoted to confirm if the satisfactory classifications 
obtained here may be achievable in age-matched control 
groups. Note that both COPD subgroups studied above 
had a comparable mean age and that even so, they could 
be classified ( table 6 ). This suggests that the observed dif-
ferences between groups indeed stem from states of dis-
ease/nondisease rather than from age differences. Simi-
larly, the COPD patients were on medications for COPD 
and comorbidities. As shown previously  [58] , our tech-
nique seems suitable for monitoring pharmacokinetics 
through exhaled breath. Thus, it is conceivable that med-
ications may be potential confounders  [59] . However, ex-
cept for a higher number of patients using inhaled ste-
roids in the COPD GOLD III/IV subgroup than in the 
GOLD I/II subgroup, these subgroups were on similar 
medications and we were able to detect differences in 
their breathprints ( fig. 2 ,  3 ;  table 5 ). Despite this limita-
tion, and given the precedent on antiepileptic drug mon-
itoring in breath  [58] , we hypothesize that this technique 
might also be useful for a better understanding of the 
mechanism of action of drugs for COPD  [60–62] .
 To our knowledge, this is the first real-time MS study 
investigating the exhaled breath of COPD patients. We 
conclude that exhaled breath can be analyzed in real time 
covering masses well beyond 300 Da. We collected 6 rep-
licate measurements per subject in <10 min, on average, 
with excellent repeatability and with a strong individual-
dependent response. A subset of mass-spectral features 
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discriminating COPD (all stages; n = 25) versus healthy 
nonsmokers (n = 25), COPD (all stages; n = 25) versus 
healthy smokers (n = 11) and mild COPD (GOLD I/II; 
n = 13) versus severe COPD (GOLD III/IV; n = 12) were 
identified. These exhaled molecules were satisfactory pre-
dictors of the presence/absence of disease and an indica-
tion of disease stage.
 This study provides a qualitative indication, suggest-
ing that real-time breath analysis could add valuable in-
formation to the current state-of-the-art in COPD diag-
nosis and phenotyping. While it is premature to conclude 
that this technique will be used routinely in the future to 
diagnose COPD as well as to understand its underlying 
mechanisms, these exploratory measurements are en-
couraging for the further pursuit of this approach.
 Acknowledgements 
 This research was supported by a Marie Curie European Rein-
tegration Grant (PMLS) within the 7th European Community 
Framework Programme (276860). René Dreier is gratefully ac-
knowledged for constructing the sampling device.
 
 References 
 1 Saetta M, Turato G, Maestrelli P, Mapp C, 
Fabbri L: Cellular and structural bases of 
chronic obstructive pulmonary disease. Am J 
Respir Crit Care Med 2001; 163: 1304–1309. 
 2 Cazzola M, Novelli G: Biomarkers in COPD. 
Pulm Pharmacol Ther 2010; 23: 493–500. 
 3 O’Reilly P, Bailey W: Clinical use of exhaled 
biomarkers in COPD. Int J Chron Obstr Pulm 
Dis 2007; 2: 403–408. 
 4 Kharitonov SA, Barnes PJ: Exhaled biomark-
ers. Chest 2006; 130: 1541–1546. 
 5 Montuschi P: Exhaled breath condensate 
analysis in patients with COPD. Clin Chim 
Acta 2005; 356: 22–34. 
 6 Biernacki WA, Kharitonov SA, Barnes PJ: In-
creased leukotriene b4 and 8-isoprostane in ex-
haled breath condensate of patients with exac-
erbations of COPD. Thorax 2003; 58: 294–298. 
 7 de Laurentiis G, Paris D, Melck D, Maniscalco 
M, Marsico S, Corso G, Motta A, Sofia M: 
Metabonomic analysis of exhaled breath con-
densate in adults by nuclear magnetic reso-
nance spectroscopy. Eur Respir J 2008; 32: 
 1175–1183. 
 8 Montuschi P, Paris D, Melck D, Lucidi V, Cia-
battoni G, Raia V, Calabrese C, Bush A, 
Barnes PJ, Motta A: NMR spectroscopy meta-
bolomic profiling of exhaled breath conden-
sate in patients with stable and unstable cystic 
fibrosis. Thorax 2012; 67: 222–228. 
 9 Motta A, Paris D, Melck D, de Laurentiis G, 
Maniscalco M, Sofia M, Montuschi P: Nucle-
ar magnetic resonance-based metabolomics 
of exhaled breath condensate: methodologi-
cal aspects. Eur Respir J 2012; 39: 498–500. 
 10 Lucidi V, Ciabattoni G, Bella S, Barnes PJ, 
Montuschi P: Exhaled 8-isoprostane and 
prostaglandin E(2) in patients with stable and 
unstable cystic fibrosis. Free Radic Biol Med 
2008; 45: 913–919. 
 11 Montuschi P, Barnes PJ, Ciabattoni G: Mea-
surement of 8-isoprostane in exhaled breath 
condensate. Methods Mol Biol 2010; 594: 73–
84. 
 12 Malerba M, Montuschi P: Non-invasive bio-
markers of lung inflammation in smoking 
subjects. Curr Med Chem 2012; 19: 187–196. 
 13 Almstrand AC, Josefson M, Bredberg A, 
Lausmaa J, Sjövall P, Larsson P, Olin AC: 
TOF-SIMS analysis of exhaled particles from 
patients with asthma and healthy controls. 
Eur Respir J 2012; 39: 59–66. 
 14 Basanta M, Jarvis RM, Xu Y, Blackburn G, Tal-
Singer R, Woodcock A, Singh D, Goodacre R, 
Paul Thomas CL, Fowler SJ: Non-invasive 
 metabolomic analysis of breath using differ-
ential mobility spectrometry in patients with 
chronic obstructive pulmonary disease and 
healthy smokers. Analyst 2010; 135: 315–320. 
 15 Fens N, De Nijs SB, Peters S, Dekker T, Kno-
bel HH, Vink TJ, Willard NP, Zwinderman 
AH, Krouwelse FH, Janssen HG, Lutter R, 
Sterk PJ: Exhaled air molecular profiling in re-
lation to inflammatory subtype and activity in 
COPD. Eur Respir J 2011; 38: 1301–1309. 
 16 Fens N, Zwinderman AH, van der Schee MP, 
de Nijs SB, Dijkers E, Roldaan AC, Cheung D, 
Bel EH, Sterk PJ: Exhaled breath profiling en-
ables discrimination of chronic obstructive 
pulmonary disease and asthma. Am J Respir 
Crit Care Med 2009; 180: 1076–1082. 
 17 Westhoff M, Litterst P, Maddula S, Bödeker B, 
Rahmann S, Davies A, Baumbach J: Differen-
tiation of chronic obstructive pulmonary dis-
ease (COPD) including lung cancer from 
healthy control group by breath analysis using 
ion mobility spectrometry. Int J Ion Mobil 
Spectrom 2010; 13: 131–139. 
 18 Van Berkel JJBN, Dallinga JW, Möller GM, 
Godschalk RWL, Moonen EJ, Wouters EFM, 
Van Schooten FJ: A profile of volatile organic 
compounds in breath discriminates COPD 
patients from controls. Respir Med 2010; 104: 
 557–563. 
 19 Montuschi P, Mores N, Trove A, Mondino C, 
Barnes PJ: The electronic nose in respiratory 
medicine. Respiration 2013; 85: 72–84. 
 20 Bofan M, Mores N, Baron M, Dabrowska M, 
Valente S, Schmid M, Trove A, Conforto S, 
Zini G, Cattani P, Fuso L, Mautone A, Mon-
dino C, Pagliari G, D’Alessio T, Montuschi P: 
Within-day and between-day repeatability of 
measurements with an electronic nose in pa-
tients with COPD. J Breath Res 2013; 7: 017103. 
 21 Ehmann R, Boedeker E, Friedrich U, Sagert J, 
Dippon J, Friedel G, Walles T: Canine scent 
detection in the diagnosis of lung cancer: re-
visiting a puzzling phenomenon. Eur Respir J 
2012; 39: 669–676. 
 22 Martínez-Lozano P, de la Mora JF: Electro-
spray ionization of volatiles in breath. Int J 
Mass Spectrom 2007; 265: 68–72. 
 23 Martí nez-Lozano P, Ferná ndez de la Mora J: 
Direct analysis of fatty acid vapors in breath 
by electrospray ionization and atmospheric 
pressure ionization-mass spectrometry. Anal 
Chem 2008; 80: 8210–8215. 
 24 Martínez-Lozano P, Zingaro L, Finiguerra A, 
Cristoni S: Secondary electrospray ioniza-
tion-mass spectrometry: breath study on a 
control group. J Breath Res 2011; 5: 016002. 
 25 Martínez-Lozano Sinues P, Kohler M, Ze-
nobi R: Monitoring diurnal changes in ex-
haled human breath. Anal Chem 2013; 85: 
 369–373. 
 26 Martínez-Lozano P, Fernández de la Mora J: 
Direct analysis of fatty acid vapors in breath 
by electrospray ionization and atmospheric 
pressure ionization-mass spectrometry. Ana-
lytical Chemistry 2008; 80: 8210–8215. 
 27 Martínez-Lozano P, Fernández de la Mora J: 
Electrospray ionization of volatiles in breath. 
Int J Mass Spectrom 2007; 265: 68–72. 
 28 Berchtold C, Meier L, Steinhoff R, Zenobi R: 
A new strategy based on real-time secondary 
electrospray ionization and high-resolution 
mass spectrometry to discriminate endoge-
nous and exogenous compounds in exhaled 
breath. Metabolomics 2013, DOI: 10.1007/
s11306-013-0568-z. 
 29 Wu C, Siems WF, Hill HH: Secondary elec-
trospray ionization ion mobility spectrome-
try/mass spectrometry of illicit drugs. Anal 
Chem 2000; 72: 396–403. 
 30 Zhu J, Bean HD, Jiménez-Díaz J, Hill JE: 
Secondary electrospray ionization-mass 
spectrometry (SESI-MS) breathprinting of 
multiple bacterial lung pathogens, a mouse 
model study. J Appl Physiol 2013; 114: 1544–
1549. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
3/
20
16
 2
:4
2:
30
 P
M
 Martinez-Lozano Sinues   et al.
 
Respiration 2014;87:301–310
DOI: 10.1159/000357785
310
 31 Jiangjiang Z, Heather DB, Matthew JW, Lau-
rie WL, Jane EH: Detecting bacterial lung in-
fections: in vivo evaluation of in vitro volatile 
fingerprints. J Breath Res 2013; 7: 016003. 
 32 Jiangjiang Z, Jaime J-D, Heather DB, Nirav 
AD, Minara IA, Lennart KAL, Jane EH: Ro-
bust detection of  P. aeruginosa and  S. aureus 
acute lung infections by secondary electro-
spray ionization-mass spectrometry (SESI-
MS) breathprinting: from initial infection to 
clearance. J Breath Res 2013; 7: 037106. 
 33 Zhu J, Bean HD, Wargo M, Leclair L, Hill JE: 
Detecting bacterial lung infections: in vivo 
evaluation of in vitro volatile fingerprints. J 
Breath Res 2013; 7: 016003. 
 34 Bean HD, Zhu J, Hill JE: Characterizing bac-
terial volatiles using secondary electrospray 
ionization mass spectrometry (SESI-MS). J 
Vis Exp 2011:e2664. 
 35 Westhoff M, Litterst P, Freitag L, Urfer W, 
Bader S, Baumbach JI: Ion mobility spectrom-
etry for the detection of volatile organic com-
pounds in exhaled breath of patients with 
lung cancer: results of a pilot study. Thorax 
2009; 64: 744–748. 
 36 National Institutes of Health: Global Initia-
tive for Chronic Obstructive Lung Disease. 
NHLBI/WHO Workshop Report 2001 (pub 
No. 2701). 
 37 Martinez-Lozano Sinues P, Criado E, Vidal G: 
Mechanistic study on the ionization of trace 
gases by an electrospray plume. Int J Mass 
Spectrom 2012; 313: 21–29. 
 38 Vidakovic B: Statistics for Bioengineering Sci-
ences: With MATLAB and WinBUGS Sup-
port. New York, Springer, 2011. 
 39 van den Berg R, Hoefsloot H, Westerhuis J, 
Smilde A, van der Werf M: Centering, scaling, 
and transformations: improving the biologi-
cal information content of metabolomics 
data. BMC Genom 2006; 7: 142. 
 40 Jackson JE: A User’s Guide to Principal Com-
ponents. Hoboken, Wiley, 2005. 
 41 Martinez-Lozano Sinues P, Kohler M, Zenobi 
R: Human breath analysis may support the 
existence of individual metabolic phenotypes. 
PLoS ONE 2013; 8:e59909. 
 42 Barnes PJ: Future perspectives on exhaled 
biomarkers. Eur Respir Soc J 2010; 49: 237–
246. 
 43 McKenzie JH, McDevitt JJ, Fabian MP, 
Hwang GM, Milton DK: Collection of aero-
solized human cytokines using Teflon ® fil-
ters. PLoS ONE 2012; 7:e35814. 
 44 Phillips CO, Syed Y, Parthaláin NM, Zwigge-
laar R, Claypole TC, Lewis KE: Machine 
learning methods on exhaled volatile organic 
compounds for distinguishing COPD pa-
tients from healthy controls. J Breath Res 
2012; 6: 036003. 
 45 Lindinger W, Hansel A, Jordan A: On-line 
monitoring of volatile organic compounds at 
PPTV levels by means of proton-transfer-re-
action mass spectrometry (PTR-MS) medical 
applications, food control and environmental 
research. Int J Mass Spectrom Ion Processes 
1998; 173: 191–241. 
 46 Smith D, Španěl P: Selected ion flow tube 
mass spectrometry (SIFT-MS) for on-line 
trace gas analysis. Mass Spectrom Rev 2005; 
 24: 661–700. 
 47 Spanel P, Dryahina K, Rejskova A, Chippen-
dale TWE, Smith D: Breath acetone concen-
tration; biological variability and the influ-
ence of diet. Physiol Meas 2011; 32:N23–N31. 
 48 Schwarz K, Pizzini A, Arendacká B, Zerlauth 
K, Filipiak W, Schmid A, Dzien A, Neuner S, 
Lechleitner M, Scholl-Bürgi S, Miekisch W, 
Schubert J, Unterkofler K, Witkovský V,  Gastl 
G, Amann A: Breath acetone – aspects of nor-
mal physiology related to age and gender as 
determined in a PTR-MS study. J Breath Res 
2009; 3: 027003. 
 49 Martínez-Lozano P, Rus J, Fernández de la 
Mora G, Hernández M, Fernández de la Mora 
J: Secondary electrospray ionization (SESI) of 
ambient vapors for explosive detection at 
concentrations below parts per trillion. J Am 
Soc Mass Spectrom 2009; 20: 287–294. 
 50 Chen H, Wortmann A, Zhang W, Zenobi R: 
Rapid in vivo fingerprinting of nonvolatile 
compounds in breath by extractive electro-
spray ionization quadrupole time-of-flight 
mass spectrometry. Angew Chem Int Ed Engl 
2007; 46: 580–583. 
 51 Fernandez de la Mora J: Ionization of vapor 
molecules by an electrospray cloud. Int J Mass 
Spectrom 2011; 300: 182–193. 
 52 Ross B: Sub-parts per billion detection of trace 
volatile chemicals in human breath using se-
lected ion flow tube mass spectrometry. BMC 
Res Notes 2008; 1: 41. 
 53 Turner MA, Bandelow S, Edwards L, Patel P, 
Martin HJ, Wilson ID, Thomas CLP: The ef-
fect of a paced auditory serial addition test 
(PASAT) intervention on the profile of vola-
tile organic compounds in human breath: a 
pilot study. J Breath Res 2013; 7: 017102. 
 54 Van den Velde S, Nevens F, Van hee P, van 
Steenberghe D, Quirynen M: GC-MS analysis 
of breath odor compounds in liver patients. J 
Chromatogr B 2008; 875: 344–348. 
 55 Gambhir KK, McMenamy RH, Watson F: Po-
sitions in human serum albumin which in-
volve the indole binding site. Sequence of 
107-residue fragment. J Biol Chem 1975; 250: 
 6711–6719. 
 56 Assfalg M, Bertini I, Colangiuli D, Luchinat C, 
Schäfer H, Schütz B, Spraul M: Evidence of 
different metabolic phenotypes in humans. 
Proc Natl Acad Sci 2008; 105: 1420–1424. 
 57 Montuschi P: Toward a personalized phar-
macotherapy of respiratory diseases. Front 
Pharmacol 2010; 1: 131. 
 58 Gamez G, Zhu L, Disko A, Chen H, Azov V, 
Chingin K, Kramer G, Zenobi R: Real-time, in 
vivo monitoring and pharmacokinetics of 
valproic acid via a novel biomarker in exhaled 
breath. Chem Commun 2011; 47: 4884–4886. 
 59 Montuschi P: Pharmacological treatment of 
chronic obstructive pulmonary disease. Int J 
Chron Obstr Pulmon Dis 2006; 1: 409. 
 60 Martinez-Lozano Sinues P, Zenobi R, Kohler 
M: Analysis of the exhalome: a diagnostic tool 
of the future. Chest J 2013; 144: 746–749. 
 61 Fuso L, Mores N, Valente S, Malerba M, Mon-
tuschi P: Long-acting beta-agonists and their 
association with inhaled corticosteroids in 
COPD. Curr Med Chem 2013; 20: 1477–1495. 
 62 Montuschi P, Macagno F, Valente S, Fuso L: 
Inhaled muscarinic acetylcholine receptor 
antagonists for treatment of COPD. Curr 
Med Chem 2013; 20: 1464–1476. 
 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
3/
20
16
 2
:4
2:
30
 P
M
